REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Rating of “Moderate Buy” from Analysts

REGENXBIO Inc. (NASDAQ:RGNX) has earned an average rating of “Moderate Buy” from the nine research firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $30.00.

RGNX has been the subject of several research reports. Stifel Nicolaus lifted their price target on REGENXBIO from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Friday, December 19th. Royal Bank Of Canada increased their price objective on REGENXBIO from $17.00 to $19.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. HC Wainwright reissued a “buy” rating and set a $34.00 target price on shares of REGENXBIO in a report on Tuesday, October 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of REGENXBIO in a research report on Wednesday, October 8th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $52.00 price target on shares of REGENXBIO in a research report on Thursday, November 20th.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. State of Alaska Department of Revenue acquired a new stake in shares of REGENXBIO in the third quarter valued at approximately $25,000. Aquatic Capital Management LLC bought a new stake in shares of REGENXBIO during the 3rd quarter valued at $37,000. Jones Financial Companies Lllp grew its holdings in shares of REGENXBIO by 44.4% during the 3rd quarter. Jones Financial Companies Lllp now owns 4,133 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 1,270 shares in the last quarter. Steward Partners Investment Advisory LLC increased its position in shares of REGENXBIO by 754.1% in the second quarter. Steward Partners Investment Advisory LLC now owns 5,663 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 5,000 shares during the period. Finally, Captrust Financial Advisors bought a new stake in REGENXBIO during the second quarter worth about $85,000. 88.08% of the stock is owned by institutional investors.

REGENXBIO Stock Performance

Shares of RGNX opened at $13.76 on Friday. The firm has a market cap of $696.53 million, a P/E ratio of -3.97 and a beta of 1.07. REGENXBIO has a 52 week low of $5.03 and a 52 week high of $15.84. The firm’s 50-day simple moving average is $13.27 and its 200 day simple moving average is $10.95.

REGENXBIO (NASDAQ:RGNX) last issued its quarterly earnings data on Thursday, November 6th. The biotechnology company reported ($1.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.38) by $0.18. REGENXBIO had a negative net margin of 110.29% and a negative return on equity of 78.29%. The firm had revenue of $29.73 million during the quarter, compared to the consensus estimate of $24.41 million. As a group, equities analysts forecast that REGENXBIO will post -4.84 earnings per share for the current year.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.